Patents by Inventor Philip A. Lane
Philip A. Lane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240173173Abstract: Medical tubing securement apparatuses may be configured as a stamped projection of a film including a living hinge and one or more securement catches. In particular, described herein are urinary catheter securement devices and IV securement devices. These medical tubing securement apparatuses may be three-dimensional adhesive medical devices having a layer of material that was formed by stamping or pressing a sheet of the material into a complex 3D shape capable of supporting a medical tubing (e.g., urinary catheter and/or IV line).Type: ApplicationFiled: December 1, 2023Publication date: May 30, 2024Inventors: Rajiv DOSHI, Kenneth CHOU, Arthur G. SANDOVAL, Robert Charles LANE, Gabriel Philip HOWLES-BANERJI, Michael Lawrence FAVET
-
Publication number: 20220372125Abstract: The present disclosure relates to an antigen specific binding domain which binds to RON (Macrophage Stimulating Protein Receptor or Recepteur d'Origine Nantais). The disclosure also extends to chimeric antigen receptors (and a cell expressing the same), antibody molecules (including full length antibodies and fragments thereof, as well as antibody conjugates) containing the antigen binding domains disclosed herein. Also disclosed herein are pharmaceutical compositions comprising the cells, antibody molecules as disclosed herein. The present disclosure also refers to the use of the antigen binding domains, the chimeric antigen receptors, the antibody molecules and the pharmaceutical compositions disclosed herein in therapy, more particularly in treating cancer. Also disclosed herein are radiolabelled antibody conjugates comprising the antigen binding domains as disclosed, and their use in methods of treatment or diagnosis.Type: ApplicationFiled: October 2, 2020Publication date: November 24, 2022Inventors: Xin Yu Koh, David Philip Lane
-
Patent number: 9994644Abstract: Antibodies specifically binding an epitope comprised in the ?-chain of c-Met, modifications, compositions and uses thereof are disclosed herein.Type: GrantFiled: March 28, 2014Date of Patent: June 12, 2018Assignee: Agency for Science, Technology and ResearchInventors: Shuxian Julin Wong, David Philip Lane
-
Patent number: 9365508Abstract: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar? are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.Type: GrantFiled: June 9, 2010Date of Patent: June 14, 2016Assignees: University Court of the University of St Andrews, University Court of the University of DundeeInventors: Sonia Lain, Nicholas James Westwood, David Philip Lane
-
Publication number: 20160083479Abstract: Antibodies specifically binding an epitope comprised in the ?-chain of c-Met, modifications, compositions and uses thereof are disclosed herein.Type: ApplicationFiled: March 28, 2014Publication date: March 24, 2016Inventors: Shuxian Julin Wong, David Philip Lane
-
Publication number: 20160046672Abstract: The present invention relates to cross-linked peptides that are associated with human eIF4G and bind to eIF4E, uses thereof and pharmaceutical compositions comprising the peptides.Type: ApplicationFiled: February 28, 2014Publication date: February 18, 2016Inventors: Christopher John Brown, David Philip Lane, Soo Tng Quah, Dilraj Lama, Chandra Shekhar Verma
-
Publication number: 20150276755Abstract: The present disclosure provides a method of determining resistance of a biological molecule to inhibition of its interaction with a target molecule by an inhibitor of the biological molecule, the method comprising the steps of: a) co-compartmentalizing a gene encoding the biological molecule with the target molecule, or a gene encoding the biological molecule with a gene encoding the target molecule into an aqueous droplet disposed within a water-in-oil emulsion, and b) assaying for a complex comprising the biological molecule and the target molecule upon expression of the gene encoding the biological molecule and the gene encoding the target molecule, wherein detection of the complex in the presence of the inhibitor indicates that the biological molecule is resistant to inhibition of its interaction with the target molecule by the inhibitor. Also provided are mutated HDM2 ubiquitin ligase polypeptides exhibiting resistance to Nutlin inhibition of p53 binding.Type: ApplicationFiled: October 25, 2013Publication date: October 1, 2015Inventors: Farid Ghadessy, Chandra Shekhar Verma, David Philip Lane, Jia Wei Siau, Thomas Leonard Joseph, Adelene Yen Ling Sim
-
Publication number: 20120149778Abstract: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar? are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.Type: ApplicationFiled: June 9, 2010Publication date: June 14, 2012Inventors: Sonia Lain, Nicholas James Westwood, David Philip Lane
-
Publication number: 20090139844Abstract: A dielectric insulated mechanical switch is coupled to a capacitive energy storage arrangement and a pulse forming network. The dielectric insulated mechanical switch is immersed in a dielectric substance. A controller is coupled to the dielectric insulated mechanical switch. The controller is programmed to selectively open and close the dielectric insulated mechanical switch so as to supply energy stored in the capacitive energy storage device to the pulse forming network and thereby form a high voltage energy pulse.Type: ApplicationFiled: February 3, 2009Publication date: June 4, 2009Applicant: L-3 Communications Corporation, a Delaware corporationInventors: Charles Crain, Philip Lane, John McClure, James Youngman
-
Patent number: 7485989Abstract: A system for generating a high voltage energy pulse comprises a capacitive energy storage arrangement that is coupled to a direct current (DC) power supply. The capacitive energy storage arrangement stores energy from the power supply. The system also includes a pulse forming network for forming frequency contents of a high voltage energy pulse. A dielectric insulated mechanical switch is coupled to the capacitive energy storage arrangement and the pulse forming network. The dielectric insulated mechanical switch is immersed in a dielectric substance. A controller is coupled to the dielectric insulated mechanical switch. The controller is programmed to selectively open and close the dielectric insulated mechanical switch so as to supply energy stored in the capacitive energy storage device to the pulse forming network and thereby form the high voltage energy pulse.Type: GrantFiled: September 20, 2006Date of Patent: February 3, 2009Assignee: L-3 Communications CorporationInventors: Charles Crain, Philip Lane, John McClure, James Youngman
-
Publication number: 20080249025Abstract: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation and cellular proliferation, indicative of therapeutic usefullness in treatment of tumors and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.Type: ApplicationFiled: June 4, 2008Publication date: October 9, 2008Applicant: Cyclacel LimitedInventors: Kathryn Lindsay Ball, David PHilip Lane
-
Publication number: 20080068027Abstract: A monitoring system in accordance with one embodiment comprising a plurality of surge arrestors; a plurality of probes coupled, each one of the plurality of probes coupled to one of the plurality of surge arrestors; the plurality of probes comprising at least one current probe and at least one voltage probe; a switching matrix coupled to the plurality of probes; and an electronic measuring device coupled to the switch, the electronic measuring device for measuring signals from the plurality of probes, the signals corresponding to a status of each of the plurality the surge arrestors.Type: ApplicationFiled: September 20, 2006Publication date: March 20, 2008Inventors: Charles Crain, Philip Lane, Kelly Rice, James Youngman
-
Publication number: 20080067875Abstract: A system for generating a high voltage energy pulse comprises a capacitive energy storage arrangement that is coupled to a direct current (DC) power supply. The capacitive energy storage arrangement stores energy from the power supply. The system also includes a pulse forming network for forming frequency contents of a high voltage energy pulse. A dielectric insulated mechanical switch is coupled to the capacitive energy storage arrangement and the pulse forming network. The dielectric insulated mechanical switch is immersed in a dielectric substance. A controller is coupled to the dielectric insulated mechanical switch. The controller is programmed to selectively open and close the dielectric insulated mechanical switch so as to supply energy stored in the capacitive energy storage device to the pulse forming network and thereby form the high voltage energy pulse.Type: ApplicationFiled: September 20, 2006Publication date: March 20, 2008Inventors: Charles Crain, Philip Lane, John McClure, James Youngman
-
Patent number: 7141541Abstract: We claim a therapeutic method of inducing programmed cell death comprising administering to a recipient a peptide of 10–25 amino acids, comprising the sequence: (KR)xxYxxx(F/Q)L(L/M) wherein x is any amino acid.Type: GrantFiled: June 21, 2000Date of Patent: November 28, 2006Assignee: University Court of the University of DundeeInventors: Christopher Gregory Proud, Terrence Patrick Herbert, David Philip Lane, Robin Fahraeus
-
Patent number: 7113708Abstract: A data communications link uses a multi-power level optical source to encode and transmit data words along a communications channel to a receiver station. A received signal condition monitor senses the level of a pre-determined characteristic and transmits a control signal to a controller which controls the power output of the optical source.Type: GrantFiled: November 9, 1999Date of Patent: September 26, 2006Assignee: Barr & Stroud LimitedInventors: Stephen Creaney, Philip Lane, Richard John Ferguson, Thomas Crummey
-
Patent number: 7083983Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.Type: GrantFiled: July 4, 1997Date of Patent: August 1, 2006Assignee: Cancer Research Campaign Technology LimitedInventors: David Philip Lane, Volker Böttger, Angelika Böttger, Steven Michael Picksley, Heinz-Kurt Hochkeppel, Carlos Garcia-Echeverria, Patrick Chène, Pascal Furet
-
Patent number: 6962792Abstract: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation, and cellular proliferation, indicative of therapeutic usefulness in treatment of tumours and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.Type: GrantFiled: May 8, 1997Date of Patent: November 8, 2005Assignee: Cyclacel LimitedInventors: Kathryn Lindsay Ball, David Philip Lane
-
Publication number: 20040214765Abstract: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation, and cellular proliferation, indicative of therapeutic usefulness in treatment of tumours and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.Type: ApplicationFiled: August 22, 2003Publication date: October 28, 2004Inventors: Kathryn Lindsay Ball, David Philip Lane
-
Publication number: 20040146971Abstract: The present invention relates to a protein which is induced by p53 and which promotes apoptosis. The present invention also relates to the gene encoding the protein as well as vectors and the like comprising the gene and also uses the gene/protein associated with promoting apoptosis.Type: ApplicationFiled: February 24, 2004Publication date: July 29, 2004Inventors: David Philip Lane, Jean-Christophe Bourdon, Jochen Renzing
-
Patent number: 6754240Abstract: An isochronous output data stream format which is time multiplexed and has a fixed time period where input isochronous data streams are multiplexed into the output isochronous data stream and the output data stream is the same data rate as the fastest input isochronous data stream. One or more of the input data streams contain a code which has been run length limited and/or has a zero running digital sum with banded disparity. In another embodiment, an isochronous output data stream format which is time multiplexed and has a fixed time period where input isochronous data streams are multiplexed into the output isochronous data stream and the output data stream is the sum of the maximum input isochronous data streams. One or more of the data streams contain a code which has been run length limited and/or has a zero running digital sum with banded disparity.Type: GrantFiled: July 14, 1999Date of Patent: June 22, 2004Assignee: International Business Machines CorporationInventors: Thomas Crummey, Richard John Fergusson, Shaun Kerigan, Philip Lane